



Sosei assigns SD118 assets to Beijing Tide Pharmaceutical

Tokyo, Japan – 13 August 2012: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd. (“Sosei KK”), has assigned its rights to the assets of SD118 to a Chinese pharmaceutical company, Beijing Tide Pharmaceutical Co., Ltd (“Beijing Tide”). Sosei KK, together with its co-development partner, NeuroDiscovery Ltd. had been developing SD118 for the treatment of neuropathic pain.

SD118 was previously under investigation in Japan for a different indication, but following re-profiling has demonstrated its potential as a new therapy for neuropathic pain.

Sosei KK decided to assign its rights for SD118 in order to prioritize and focus development resources. Under the terms of the agreement, Sosei KK will receive payments from Beijing Tide based on revenues arising from the commercialization of SD118.

- Ends -

Enquiries:

Sosei Group Corporation	
Tokyo Office	London Office
Milica STOJKOVIC Investor Relations	Kathryn LYDON, PA to CEO & Corporate Communication
+81-(0)3-5210-3399	+44-(0)20-7691-0983
mstojkovic@sosei.com	klydon@sosei.com

Notes for Editors:

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit www.osei.com.

About Beijing Tide Pharmaceutical

Beijing Tide is the first developer and manufacturer of lipid microsphere targeting drugs in China. It is also the first Chinese pharmaceutical company exporting sterile injections to Japan with Japanese GMP certificate.

For more information, visit the Beijing Tide Pharmaceutical web site at http://www.tidepharm.com/web_us/index.html